{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,6]],"date-time":"2026-03-06T16:03:42Z","timestamp":1772813022378,"version":"3.50.1"},"reference-count":74,"publisher":"Springer Science and Business Media LLC","issue":"4","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["International Journal of Hematology"],"published-print":{"date-parts":[[2004,5,1]]},"DOI":"10.1532\/ijh97.04050","type":"journal-article","created":{"date-parts":[[2007,10,18]],"date-time":"2007-10-18T13:52:32Z","timestamp":1192715552000},"page":"311-321","source":"Crossref","is-referenced-by-count":13,"title":["Treatment of Indolent Non-Hodgkin's Lymphoma with Cladribine as Single-Agent Therapy and in Combination with Mitoxantrone"],"prefix":"10.1007","volume":"79","author":[{"given":"James O.","family":"Armitage","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kensei","family":"Tobinai","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dieter","family":"Hoelzer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mathias J.","family":"Rummel","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","reference":[{"key":"E00001","doi-asserted-by":"crossref","first-page":"3835","DOI":"10.1200\/JCO.1999.17.12.3835","volume":"17","author":"Harris","year":"1999","unstructured":"Harris NL, Jaffe ES, Diebold J, et al. World Health Organization classification of neoplastic diseases of the hematopoietic and lymphoid tissues: report of the Clinical Advisory Committee meeting--Airlie House,Virginia, November 1997. J Clin Oncol. 1999;17: 3835-3849.","journal-title":"J Clin Oncol"},{"key":"E00002","doi-asserted-by":"crossref","first-page":"3835","DOI":"10.1200\/JCO.1999.17.12.3835","volume":"17","author":"Harris","year":"1999","unstructured":"The International Non-Hodgkin's Lymphoma Prognostic Factors Project: a predictive model for aggressive non-Hodgkin's lymphoma. N Engl J Med. 1993;329:987-994.","journal-title":"J Clin Oncol"},{"key":"E00003","doi-asserted-by":"crossref","first-page":"2780","DOI":"10.1200\/JCO.1998.16.8.2780","author":"Armitage, JO","year":"1998","unstructured":"Armitage JO, Weisenburger DD. New approach to classifying non-Hodgkin's lymphomas: clinical features of the major histologic subtypes. Non-Hodgkin's Lymphoma Classification Project. J Clin Oncol. 1998;16:2780-2795.","journal-title":"J Clin Oncol"},{"key":"E00004","doi-asserted-by":"crossref","first-page":"717","DOI":"10.1023\/A:1008265532487","author":"Anderson, JR","year":"1998","unstructured":"Anderson JR, Armitage JO, Weisenburger DD. Epidemiology of the non-Hodgkin's lymphomas: distributions of the major subtypes differ by geographic locations. Non-Hodgkin's Lymphoma Classification Project. Ann Oncol. 1998;9:717-720.","journal-title":"Ann Oncol"},{"key":"E00005","doi-asserted-by":"crossref","first-page":"3909","DOI":"10.1182\/blood.V89.11.3909","author":"The Non-Hodgkin's Lymphoma Classification, Project","year":"1997","unstructured":"The Non-Hodgkin's Lymphoma Classification Project. A clinical evaluation of the International Lymphoma Study Group classification of non-Hodgkin's lymphoma. Blood. 1997;89:3909-3918.","journal-title":"Blood"},{"key":"E00006","doi-asserted-by":"crossref","first-page":"1471","DOI":"10.1056\/NEJM198412063112303","author":"Horning, SJ","year":"1984","unstructured":"Horning SJ, Rosenberg SA. The natural history of initially untreated low-grade non-Hodgkin's lymphomas. N Engl J Med. 1984;311:1471-1475.","journal-title":"N Engl J Med"},{"key":"E00007","doi-asserted-by":"crossref","first-page":"1282","DOI":"10.1200\/JCO.1996.14.4.1282","author":"Mac Manus, MP","year":"1996","unstructured":"Mac Manus MP, Hoppe RT. Is radiotherapy curative for stage I and II low-grade follicular lymphoma? Results of a long-term followup study of patients treated at Stanford University. J Clin Oncol. 1996;14:1282-1290.","journal-title":"J Clin Oncol"},{"key":"E00008","doi-asserted-by":"crossref","first-page":"1219","DOI":"10.1016\/S0360-3016(01)01747-3","author":"Wilder, RB","year":"2001","unstructured":"Wilder RB, Jones D, Tucker SL, et al. Long-term results with radiotherapy for stage I-II follicular lymphomas. Int J Radiat Oncol Biol Phys. 2001;51:1219-1227.","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"E00009","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1016\/0360-3016(84)90028-2","author":"Gospodarowicz, MK","year":"1984","unstructured":"Gospodarowicz MK, Bush RS, Brown TC, Chua T. Prognostic factors in nodular lymphomas: a multivariate analysis based on the Princess Margaret Hospital experience. Int J Radiat Oncol Biol Phys. 1984;10:489-497.","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"E00010","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1200\/JCO.1997.15.1.52","author":"Seymour, JF","year":"1997","unstructured":"Seymour JF, Cusack JD, Lerner SA, Pollock RE, Keating MJ. Case\/ control study of the role of splenectomy in chronic lymphocytic leukemia. J Clin Oncol. 1997;15:52-60.","journal-title":"J Clin Oncol"},{"key":"E00011","doi-asserted-by":"crossref","first-page":"1470","DOI":"10.1200\/JCO.1986.4.10.1470","author":"Gallagher, CJ","year":"1986","unstructured":"Gallagher CJ, Gregory WM, Jones AE, et al. Follicular lymphoma: prognostic factors for response and survival. J Clin Oncol. 1986;4: 1470-1480.","journal-title":"J Clin Oncol"},{"key":"E00012","doi-asserted-by":"crossref","first-page":"2825","DOI":"10.1200\/JCO.1998.16.8.2825","volume":"16","author":"McLaughlin, P","year":"1998","unstructured":"McLaughlin P, Grillo-Lopez AJ, Link BK, et al. Rituximab chimeric anti-CD20 monoclonal antibody therapy for relapsed indolent lymphoma: half of patients respond to a four-dose treatment program. J Clin Oncol. 1998;16:2825-2833.","journal-title":"J Clin Oncol"},{"key":"E00013","first-page":"4261","author":"et, al","year":"2002","unstructured":"Hainsworth JD, Litchy S, Burris HA 3rd, et al. Rituximab as first-line and maintenance therapy for patients with indolent non-Hodgkin's lymphoma. J Clin Oncol. 2002;20:4261-4267.","journal-title":"J Clin Oncol"},{"key":"E00014","first-page":"161a","author":"Ghielmini, M","year":"2002","unstructured":"Ghielmini M, Hsu Schmitz S-F, Cogliatti S, et al. Prolonged treatment with rituximab significantly improves event free survival and duration of response in patients with follicular lymphoma: a randomised SAKK Trial [abstract]. Blood. 2002;100:161a.Abstract 604.","journal-title":"Blood"},{"key":"E00015","doi-asserted-by":"crossref","first-page":"1316","DOI":"10.1200\/JCO.2000.18.6.1316","volume":"18","author":"Vose, JM","year":"2000","unstructured":"Vose JM, Wahl RL, Saleh M, et al. Multicenter phase II study of iodine-131 tositumomab for chemotherapy-relapsed\/refractory low-grade and transformed low-grade B-cell non-Hodgkin's lymphomas. J Clin Oncol. 2000;18:1316-1323.","journal-title":"J Clin Oncol"},{"key":"E00016","first-page":"4a","author":"Rohatiner, AZ","year":"1998","unstructured":"Rohatiner AZ, Gregory WM, Peterson BA, Smalley RV. A meta-analysis of randomized trials evaluating the role of interferon as treatment for follicular lymphoma [abstract]. Proc Am Soc Clin Oncol. 1998;17:4a. Abstract 11.","journal-title":"Proc Am Soc Clin Oncol"},{"key":"E00017","doi-asserted-by":"crossref","first-page":"445","DOI":"10.1200\/JCO.1997.15.2.445","author":"Bierman, PJ","year":"1997","unstructured":"Bierman PJ, Vose JM, Anderson JR, Bishop MR, Kessinger A, Armitage JO. High-dose therapy with autologous hematopoietic rescue for follicular low-grade non-Hodgkin's lymphoma. J Clin Oncol. 1997;15:445-450.","journal-title":"J Clin Oncol"},{"key":"E00018","doi-asserted-by":"crossref","first-page":"3325","DOI":"10.1182\/blood.V94.10.3325.422k13_3325_3333","author":"Freedman, AS","year":"1999","unstructured":"Freedman AS, Neuberg D, Mauch P, et al. Long-term follow-up of autologous bone marrow transplantation in patients with relapsed follicular lymphoma. Blood. 1999;94:3325-3333.","journal-title":"Blood"},{"key":"E00019","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1054\/blre.1999.0125","author":"Bierman, PJ","year":"2000","unstructured":"Bierman PJ. Allogeneic bone marrow transplantation for lymphoma. Blood Rev. 2000;14:1-13.","journal-title":"Blood Rev"},{"key":"E00020","doi-asserted-by":"crossref","first-page":"640","DOI":"10.1016\/S1083-8791(00)70030-9","volume":"6","author":"Vose, JM","year":"2000","unstructured":"Vose JM, Bierman PJ,Weisenburger DD, et al.Autologous hematopoietic stem cell transplantation for mantle cell lymphoma. Biol Blood Marrow Transplant. 2000;6:640-645.","journal-title":"Biol Blood Marrow Transplant."},{"key":"E00021","doi-asserted-by":"crossref","first-page":"404","DOI":"10.1182\/blood.V97.2.404","author":"Horning, SJ","year":"2001","unstructured":"Horning SJ, Negrin RS, Hoppe RT, et al. High-dose therapy and autologous bone marrow transplantation for follicular lymphoma in first complete or partial remission: results of a phase II clinical trial. Blood. 2001;97:404-409.","journal-title":"Blood"},{"key":"E00022","first-page":"256","volume":"22","author":"O'Connor, OA","year":"2003","unstructured":"O'Connor OA, Wright J, Moskowitz C, Macgregor-Cortelli B, Straus D, Horse-Grant D. Phase II clinical experience with the pro-teasome inhibitor bortezomib (formerly PS-341) in patients with indolent lymphoma [abstract]. Proc Am Soc Clin Oncol. 2003;22: 2566. Abstract 2277.","journal-title":"Proc Am Soc Clin Oncol"},{"key":"E00023","doi-asserted-by":"crossref","first-page":"1137","DOI":"10.1016\/S0140-6736(96)11103-X","volume":"349","author":"Webb, A","year":"1997","unstructured":"Webb A, Cunningham D, Cotter F, et al. BCL-2 antisense therapy in patients with non-Hodgkin lymphoma. Lancet. 1997;349: 1137-1141.","journal-title":"Lancet"},{"key":"E00024","doi-asserted-by":"crossref","first-page":"3262","DOI":"10.1200\/JCO.2002.11.017","author":"Witzig, TE","year":"2002","unstructured":"Witzig TE, Flinn IW, Gordon LI, et al. Treatment with ibritumomab tiuxetan radioimmunotherapy in patients with rituximab-refractory follicular non-Hodgkin's lymphoma. J Clin Oncol. 2002;20:3262-3269.","journal-title":"J Clin Oncol"},{"key":"E00025","doi-asserted-by":"crossref","first-page":"3918","DOI":"10.1200\/JCO.2001.19.19.3918","volume":"19","author":"Kaminski, MS","year":"2001","unstructured":"Kaminski MS, Zelenetz AD, Press OW, et al. Pivotal study of iodine I 131 tositumomab for chemotherapy-refractory low-grade or transformed low-grade B-cell non-Hodgkin's lymphomas. J Clin Oncol. 2001;19:3918-3928.","journal-title":"J Clin Oncol"},{"key":"E00026","first-page":"88","author":"Czuczman, MS","year":"1999","unstructured":"Czuczman MS. CHOP plus rituximab chemoimmunotherapy of indolent B-cell lymphoma. Semin Oncol. 1999;26(suppl 14):88-96.","journal-title":"Semin Oncol"},{"key":"E00027","first-page":"28a","volume":"102","author":"Marcus","year":"2003","unstructured":"Marcus R, Imrie K, Belch A, et al. An international multi-centre, randomized, open-label, phase III trial comparing rituximab added to CVP chemotherapy to CVP chemotherapy alone in untreated stage III\/IV follicular non-Hodgkin's lymphoma [abstract]. Blood. 2003;102:28a. Abstract 87.","journal-title":"Blood"},{"key":"E00028","first-page":"273a","volume":"102","author":"Byrd","year":"2003","unstructured":"Byrd JC, Rai KR, Peterson BL, Appelbaum FR, Morrison VA, Kolitz JEA. The addition of rituximab to fludarabine significantly improves progression-free and overall survival in previously untreated chronic lymphocytic leukemia (CLL) patients [abstract]. Blood. 2003;102:273a. Abstract 245.","journal-title":"Blood"},{"key":"E00029","doi-asserted-by":"crossref","first-page":"1840","DOI":"10.1182\/blood.V94.6.1840","volume":"94","author":"Damle, RN","year":"1999","unstructured":"Damle RN, Wasil T, Fais F, et al. Ig V gene mutation status and CD38 expression as novel prognostic indicators in chronic lymphocytic leukemia. Blood. 1999;94:1840-1847.","journal-title":"Blood"},{"key":"E00030","doi-asserted-by":"crossref","first-page":"1764","DOI":"10.1056\/NEJMoa023143","volume":"348","author":"Crespo, M","year":"2003","unstructured":"Crespo M, Bosch F, Villamor N, et al. ZAP-70 expression as a surrogate for immunoglobulin-variable-region mutations in chronic lymphocytic leukemia. N Engl J Med. 2003;348:1764-1775.","journal-title":"N Engl J Med"},{"key":"E00031","first-page":"100a","author":"Wierda, WG","year":"2003","unstructured":"Wierda WG, O'Brien S, Faderl S, et al. Improved survival in patients with relapsed-refractory chronic lymphocytic leukemia (CLL) treated with fludarabine, cyclophosphamide, and rituximab (FCR) combination [abstract]. Blood. 2003;102:100a. Abstract 373.","journal-title":"Blood"},{"key":"E00032","doi-asserted-by":"crossref","first-page":"6865","DOI":"10.1073\/pnas.77.11.6865","volume":"77","author":"Carson, DA","year":"1980","unstructured":"Carson DA, Wasson DB, Kaye J, et al. Deoxycytidine kinase-mediated toxicity of deoxyadenosine analogs toward malignant human lymphoblasts in vitro and toward murine L1210 leukemia in vivo. Proc Natl Acad Sci U S A. 1980;77:6865-6869.","journal-title":"Proc Natl Acad Sci U S A"},{"key":"E00033","doi-asserted-by":"crossref","first-page":"1117","DOI":"10.1056\/NEJM199004193221605","volume":"322","author":"Piro, LD","year":"1990","unstructured":"Piro LD, Carrera CJ, Carson DA, Beutler E. Lasting remissions inhairy-cell leukemia induced by a single infusion of 2-chlorodeoxyadenosine. N Engl J Med. 1990;322:1117-1121.","journal-title":"N Engl J Med"},{"key":"E00034","doi-asserted-by":"crossref","first-page":"2203","DOI":"10.1182\/blood.V80.9.2203.2203","volume":"80","author":"Tallman, MS","year":"1992","unstructured":"Tallman MS, Hakimian D, Variakojis D, et al. A single cycle of 2-chlorodeoxyadenosine results in complete remission in the majority of patients with hairy cell leukemia. Blood. 1992;80:2203-2209.","journal-title":"Blood"},{"key":"E00035","doi-asserted-by":"crossref","first-page":"679","DOI":"10.1200\/JCO.1993.11.4.679","volume":"11","author":"Juliusson, G","year":"1993","unstructured":"Juliusson G, Liliemark J. High complete remission rate from 2-chloro-23-deoxyadenosine in previously treated patients with B-cell chronic lymphocytic leukemia: response predicted by rapid decrease of blood lymphocyte count. J Clin Oncol. 1993;11:679-689.","journal-title":"J Clin Oncol"},{"key":"E00036","doi-asserted-by":"crossref","first-page":"1746","DOI":"10.1200\/JCO.2003.09.027","volume":"21","author":"Hainsworth","year":"2003","unstructured":"Hainsworth JD, Litchy S, Barton JH, et al. Single-agent rituximab as first-line and maintenance treatment for patients with chronic lymphocytic leukemia or small lymphocytic lymphoma: a phase II trial of the Minnie Pearl Cancer Research Network. J Clin Oncol. 2003;21:1746-1751.","journal-title":"J Clin Oncol"},{"key":"E00037","doi-asserted-by":"crossref","first-page":"4157","DOI":"10.1200\/JCO.2003.06.085","author":"Tsang, RW","year":"2003","unstructured":"Tsang RW, Gospodarowicz MK, Pintilie M, et al. Localized mucosa-associated lymphoid tissue lymphoma treated with radiation therapy has excellent clinical outcome. J Clin Oncol. 2003;21: 4157-4164.","journal-title":"J Clin Oncol"},{"key":"E00038","doi-asserted-by":"crossref","first-page":"802","DOI":"10.1182\/blood.V95.3.802.003k19_802_806","volume":"95","author":"Thieblemont, C","year":"2000","unstructured":"Thieblemont C, Berger F, Dumontet C, et al. Mucosa-associated lymphoid tissue lymphoma is a disseminated disease in one third of 158 patients analyzed. Blood. 2000;95:802-806.","journal-title":"Blood"},{"key":"E00039","first-page":"4499","volume":"11","author":"Zucca, E","year":"2000","unstructured":"Zucca E, Conconi A, Roggero E, Ascani S, Campo E, Capella C. Non-gastric MALT lymphomas: a survey of 369 European patients: the International Extranodal Lymphoma Study Group (IELSG) [abstract]. Ann Oncol. 2000;11:4499. Abstract 4440.","journal-title":"Ann Oncol"},{"key":"E00040","doi-asserted-by":"crossref","first-page":"637","DOI":"10.1023\/A:1008396618983","author":"Isaacson, PG","year":"1999","unstructured":"Isaacson PG. Gastric MALT lymphoma: from concept to cure. Ann Oncol. 1999;10:637-645.","journal-title":"Ann Oncol"},{"key":"E00041","doi-asserted-by":"crossref","first-page":"547","DOI":"10.1016\/S0140-6736(02)09711-8","author":"Fischbach, W","year":"2002","unstructured":"Fischbach W, Goebeler-Kolve M, Starostik P, Greiner A, Muller-Hermelink HK. Minimal residual low-grade gastric MALT-type lymphoma after eradication of Helicobacter pylori. Lancet. 2002; 360:547-548.","journal-title":"Lancet"},{"key":"E00042","doi-asserted-by":"crossref","first-page":"2747","DOI":"10.1200\/JCO.2003.12.011","volume":"21","author":"Schetelig","year":"2003","unstructured":"Schetelig J, Thiede C, Bornhauser M, et al. Evidence of a graft-versus-leukemia effect in chronic lymphocytic leukemia after reduced-intensity conditioning and allogeneic stem-cell transplantation: the Cooperative German Transplant Study Group. J Clin Oncol. 2003;21:2747-2753.","journal-title":"J Clin Oncol"},{"key":"E00043","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1016\/S0140-6736(00)03571-6","volume":"357","author":"Liu, H","year":"2001","unstructured":"Liu H, Ruskon-Fourmestraux A, Lavergne-Slove A, et al. Resistance of t(11;18) positive gastric mucosa-associated lymphoid tissue lymphoma to Helicobacter pylori eradication therapy. Lancet. 2001;357:39-40.","journal-title":"Lancet"},{"key":"E00044","doi-asserted-by":"crossref","first-page":"952","DOI":"10.1016\/0140-6736(92)92826-2","volume":"340","author":"Beutler, E","year":"1992","unstructured":"Beutler E. Cladribine (2-chlorodeoxyadenosine). Lancet. 1992;340: 952-956.","journal-title":"Lancet"},{"key":"E00045","doi-asserted-by":"crossref","first-page":"5677","DOI":"10.1073\/pnas.74.12.5677","author":"Carson, DA","year":"1977","unstructured":"Carson DA, Kaye J, Seegmiller JE. Lymphospecific toxicity in adenosine deaminase deficiency and purine nucleoside phosphorylase deficiency: possible role of nucleoside kinase(s). Proc Natl Acad Sci U S A. 1977;74:5677-5681.","journal-title":"Proc Natl Acad Sci U S A"},{"key":"E00046","doi-asserted-by":"crossref","first-page":"570","DOI":"10.1200\/JCO.1995.13.3.570","volume":"13","author":"Saven, A","year":"1995","unstructured":"Saven A, Lemon RH, Kosty M, Beutler E, Piro LD. 2-Chlorodeoxyadenosine activity in patients with untreated chronic lymphocytic leukemia. J Clin Oncol. 1995;13:570-574.","journal-title":"J Clin Oncol"},{"key":"E00047","doi-asserted-by":"crossref","first-page":"1803","DOI":"10.1200\/JCO.1997.15.5.1803","volume":"15","author":"Kurzrock, R","year":"1997","unstructured":"Kurzrock R, Strom SS, Estey E, et al. Second cancer risk in hairy cell leukemia: analysis of 350 patients. J Clin Oncol. 1997;15:1803-1810.","journal-title":"J Clin Oncol"},{"key":"E00048","doi-asserted-by":"crossref","first-page":"559","DOI":"10.3109\/10428190009148404","volume":"36","author":"Chow","year":"2000","unstructured":"Chow KU, Rummel MJ, Weidmann E, et al. Induction of apoptosis by 2-chloro-23deoxyadenosine (2-CdA) alone and in combination with other cytotoxic drugs: synergistic effects on normal and neoplastic lymphocytes by addition of doxorubicin and mitoxantrone. Leuk Lymphoma. 2000;36:559-567.","journal-title":"Leuk Lymphoma"},{"key":"E00049","doi-asserted-by":"crossref","first-page":"2139","DOI":"10.1200\/JCO.1996.14.7.2139","author":"Saven, A","year":"1996","unstructured":"Saven A, Lee T, Kosty M, Piro L. Cladribine and mitoxantrone dose escalation in indolent non-Hodgkin's lymphoma. J Clin Oncol. 1996;14:2139-2144.","journal-title":"J Clin Oncol"},{"key":"E00050","doi-asserted-by":"crossref","first-page":"850","DOI":"10.1200\/JCO.1998.16.3.850","author":"Betticher, DC","year":"1998","unstructured":"Betticher DC, von Rohr A, Ratschiller D, et al. Fewer infections, but maintained antitumor activity with lower-dose versus standard-dose cladribine in pretreated low-grade non-Hodgkin's lymphoma. J Clin Oncol. 1998;16:850-858.","journal-title":"J Clin Oncol"},{"key":"E00051","doi-asserted-by":"crossref","first-page":"721","DOI":"10.1023\/A:1008273131598","volume":"9","author":"Betticher","year":"1998","unstructured":"Betticher DC, Ratschiller D, Hsu Schmitz SF, et al. Reduced dose of subcutaneous cladribine induces identical response rates but decreased toxicity in pretreated chronic lymphocytic leukaemia: Swiss Group for Clinical Cancer Research (SAKK). Ann Oncol. 1998;9:721-726.","journal-title":"Ann Oncol"},{"key":"E00052","doi-asserted-by":"crossref","first-page":"359","DOI":"10.3109\/10428199909167397","volume":"32","author":"Robak, T","year":"1999","unstructured":"Robak T, Gora-Tybor J, Urbanska-Rys H, Krykowski E. Combination regimen of 2-chlorodeoxyadenosine (cladribine), mitox-antrone and dexamethasone (CMD) in the treatment of refractory and recurrent low grade non-Hodgkin's lymphoma. Leuk Lymphoma. 1999;32:359-363.","journal-title":"Leuk Lymphoma"},{"key":"E00053","doi-asserted-by":"crossref","first-page":"1821","DOI":"10.1200\/JCO.1992.10.11.1821","volume":"10","author":"Barton, K","year":"1992","unstructured":"Barton K, Larson RA, O'Brien S, Ratain MJ. Rapid response of B-cell prolymphocytic leukemia to 2-chlorodeoxyadenosine. J Clin Oncol. 1992;10:1821.","journal-title":"J Clin Oncol"},{"key":"E00054","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1200\/JCO.1992.10.3.371","volume":"10","author":"Kay, AC","year":"1992","unstructured":"Kay AC, Saven A, Carrera CJ, et al. 2-Chlorodeoxyadenosine treatment of low-grade lymphomas. J Clin Oncol. 1992;10:371-377.","journal-title":"J Clin Oncol"},{"key":"E00055","doi-asserted-by":"crossref","first-page":"788","DOI":"10.1200\/JCO.1994.12.4.788","volume":"12","author":"Hoffman, M","year":"1994","unstructured":"Hoffman M,Tallman MS, Hakimian D, et al. 2-Chlorodeoxyadenosine is an active salvage therapy in advanced indolent non-Hodgkin's lymphoma. J Clin Oncol. 1994;12:788-792.","journal-title":"J Clin Oncol"},{"key":"E00056","doi-asserted-by":"crossref","first-page":"1710","DOI":"10.1182\/blood.V86.5.1710.bloodjournal8651710","volume":"86","author":"Saven, A","year":"1995","unstructured":"Saven A, Emanuele S, Kosty M, Koziol J, Ellison D, Piro L. 2-Chlorodeoxyadenosine activity in patients with untreated, indolent non-Hodgkin's lymphoma. Blood. 1995;86:1710-1716.","journal-title":"Blood"},{"key":"E00057","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1093\/jjco\/27.3.146","volume":"27","author":"Tobinai, K","year":"1997","unstructured":"Tobinai K, Ogura M, Hotta T, et al. Phase I study of cladribine (2-chlorodeoxyadenosine) in lymphoid malignancies: Cladribine Study Group. Jpn J Clin Oncol. 1997;27:146-153.","journal-title":"Jpn J Clin Oncol"},{"key":"E00058","doi-asserted-by":"crossref","first-page":"250","DOI":"10.1093\/oxfordjournals.jjco.a039642","author":"Tobinai, K","year":"1993","unstructured":"Tobinai K, Kohno A, Shimada Y, et al. Toxicity grading criteria of the Japan Clinical Oncology Group: the Clinical Trial Review Committee of the Japan Clinical Oncology Group. Jpn J Clin Oncol. 1993;23:250-257.","journal-title":"Jpn J Clin Oncol"},{"key":"E00059","doi-asserted-by":"crossref","first-page":"2216","DOI":"10.1200\/JCO.1994.12.10.2216","author":"Cheson, BD","year":"1994","unstructured":"Cheson BD, Vena DA, Foss FM, Sorensen JM. Neurotoxicity of purine analogs: a review. J Clin Oncol. 1994;12:2216-2228.","journal-title":"J Clin Oncol"},{"key":"E00060","doi-asserted-by":"crossref","first-page":"428","DOI":"10.1111\/j.1365-2141.1991.tb08051.x","volume":"79","author":"Shimoyama, M","year":"1991","unstructured":"Shimoyama M. Diagnostic criteria and classification of clinical subtypes of adult T-cell leukaemia-lymphoma: a report from the Lymphoma Study Group (1984-87). Br J Haematol. 1991;79:428-437.","journal-title":"Br J Haematol"},{"key":"E00061","doi-asserted-by":"crossref","first-page":"587","DOI":"10.1182\/blood.V80.3.587.587","volume":"80","author":"Saven, A","year":"1992","unstructured":"Saven A, Carrera CJ, Carson DA, Beutler E, Piro LD. 2-Chlorodeoxyadenosine: an active agent in the treatment of cutaneous T-cell lymphoma. Blood. 1992;80:587-592.","journal-title":"Blood"},{"key":"E00062","doi-asserted-by":"crossref","first-page":"733","DOI":"10.1182\/blood.V84.3.733.733","volume":"84","author":"O'Brien, S","year":"1994","unstructured":"O'Brien S, Kurzrock R, Duvic M, et al. 2-Chlorodeoxyadenosine therapy in patients with T-cell lymphoproliferative disorders. Blood. 1994;84:733-738.","journal-title":"Blood"},{"key":"E00063","doi-asserted-by":"crossref","first-page":"906","DOI":"10.1182\/blood.V87.3.906.bloodjournal873906","volume":"87","author":"Kuzel, TM","year":"1996","unstructured":"Kuzel TM, Hurria A, Samuelson E, et al. Phase II trial of 2-chlorodeoxyadenosine for the treatment of cutaneous T-cell lymphoma [see comments]. Blood. 1996;87:906-911.","journal-title":"Blood"},{"key":"E00064","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1172\/JCI111710","volume":"75","author":"Seto, S","year":"1985","unstructured":"Seto S, Carrera CJ, Kubota M,Wasson DB, Carson DA. Mechanism of deoxyadenosine and 2-chlorodeoxyadenosine toxicity to nondividing human lymphocytes. J Clin Invest. 1985;75:377-383.","journal-title":"J Clin Invest"},{"key":"E00065","doi-asserted-by":"crossref","first-page":"512","DOI":"10.1007\/BF02986621","volume":"77","author":"Tobinai, K","year":"2003","unstructured":"Tobinai K, Uike N, Saburi Y, et al. Phase II study of cladribine (2-chlorodeoxyadenosine) in relapsed or refractory adult T-cell leukemia-lymphoma. Int J Hematol. 2003;77:512-517.","journal-title":"Int J Hematol"},{"key":"E00066","first-page":"222","author":"Tobinai, K","year":"2001","unstructured":"Tobinai K, Kobayashi Y, Morishima Y. Prolonged cytopenia and myelodysplastic syndrome after cladribine treatment in relapsed patients with indolent non-Hodgkin's lymphoma: results of Japanese phase II study [abstract]. Proc Am Soc Clin Oncol. 2001;20: 2228b. Abstract 2664.","journal-title":"Proc Am Soc Clin Oncol"},{"key":"E00067","doi-asserted-by":"crossref","first-page":"2454","DOI":"10.1200\/JCO.1999.17.8.2454","author":"Cheson, BD","year":"1999","unstructured":"Cheson BD,Vena DA, Barrett J, Freidlin B. Second malignancies as a consequence of nucleoside analog therapy for chronic lymphoid leukemias. J Clin Oncol. 1999;17:2454-2460.","journal-title":"J Clin Oncol"},{"key":"E00068","doi-asserted-by":"crossref","first-page":"129","DOI":"10.3109\/10428199909145712","volume":"35","author":"Rummel, MJ","year":"1999","unstructured":"Rummel MJ, Chow KU, Jager E, et al. Intermittent 2-hour-infusion of cladribine as first-line therapy or in first relapse of progressive advanced low-grade and mantle cell lymphomas. Leuk Lymphoma. 1999;35:129-138.","journal-title":"Leuk Lymphoma"},{"key":"E00069","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1038\/bjc.1993.24","volume":"67","author":"Hickish, T","year":"1993","unstructured":"Hickish T,Serafinowski P,Cunningham D,et al. 23-Chlorodeoxyadenosine: evaluation of a novel predominantly lymphocyte selective agent in lymphoid malignancies. Br J Cancer. 1993;67:139-143.","journal-title":"Br J Cancer"},{"key":"E00070","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1093\/oxfordjournals.annonc.a059040","volume":"6","author":"Dimopoulos, MA","year":"1995","unstructured":"Dimopoulos MA,Weber D, Delasalle KB, Keating M,Alexanian R. Treatment of Waldenstrom's macroglobulinemia resistant to standard therapy with 2-chlorodeoxyadenosine: identification of prognostic factors. Ann Oncol. 1995;6:49-52.","journal-title":"Ann Oncol"},{"key":"E00071","first-page":"385","volume":"1","author":"Liliemark, J","year":"1995","unstructured":"Liliemark J, Juliusson G. Cellular pharmacokinetics of 2-chloro-23-deoxyadenosine nucleotides: comparison of intermittent and continuous intravenous infusion and subcutaneous and oral administration in leukemia patients. Clin Cancer Res. 1995;1:385-390.","journal-title":"Clin Cancer Res"},{"key":"E00072","doi-asserted-by":"crossref","first-page":"1514","DOI":"10.1200\/JCO.1992.10.10.1514","volume":"10","author":"Liliemark, J","year":"1992","unstructured":"Liliemark J, Albertioni F, Hassan M, Juliusson G. On the bioavailability of oral and subcutaneous 2-chloro-23-deoxyadenosine in humans: alternative routes of administration. J Clin Oncol. 1992;10: 1514-1518.","journal-title":"J Clin Oncol"},{"key":"E00073","doi-asserted-by":"crossref","first-page":"989","DOI":"10.1200\/JCO.1995.13.4.989","volume":"13","author":"Juliusson, G","year":"1995","unstructured":"Juliusson G, Heldal D, Hippe E, et al. Subcutaneous injections of 2-chlorodeoxyadenosine for symptomatic hairy cell leukemia. J Clin Oncol. 1995;13:989-995.","journal-title":"J Clin Oncol"},{"key":"E00074","doi-asserted-by":"crossref","first-page":"891","DOI":"10.1200\/JCO.2003.05.093","author":"Goodman, GR","year":"2003","unstructured":"Goodman GR, Burian C, Koziol JA, Saven A. Extended follow-up of patients with hairy cell leukemia after treatment with cladribine. J Clin Oncol. 2003;21:891-896.","journal-title":"J Clin Oncol"}],"container-title":["International Journal of Hematology"],"original-title":[],"link":[{"URL":"http:\/\/www.springerlink.com\/index\/pdf\/10.1532\/IJH97.04050","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,4,27]],"date-time":"2020-04-27T07:47:08Z","timestamp":1587973628000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1532\/IJH97.04050"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2004,5,1]]},"references-count":74,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2004,5,1]]}},"alternative-id":["M2U96DWWTUVJ1DLU"],"URL":"https:\/\/doi.org\/10.1532\/ijh97.04050","relation":{},"ISSN":["0925-5710"],"issn-type":[{"value":"0925-5710","type":"print"}],"subject":[],"published":{"date-parts":[[2004,5,1]]}}}